The content on this site is intended for healthcare professionals only
Prof Jens Ricke talks to ecancer about the need to move away from pharmaceutically funded approaches to personalised medicine at the European Forum on Oncology in Berlin, May 2012.
Personalised medicine is an individual treatment for an individual patient’s unique disease. However, current clinical trials funded by pharmaceutical companies do not result in such treatments. Prof Ricke suggests selecting doctors from a large group of specialists to develop an individual plan for each patient.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Enhancing head and neck oncology: Key insights from the conference
Choosing Wisely in endometrial & cervix cancers: Medical therapy
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Overview of the management of HER2-low breast cancer patients
Spindle cell lesions of the breast
